ClinicalTrials.gg
RecruitingNCT06130826Updated Nov 3, 2026

Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer

A Phase 1 interventional study of Biopsy and Biospecimen Collection in Breast Carcinoma and Colorectal Carcinoma, sponsored by City of Hope Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by City of Hope Medical Center · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.
Updated Nov 3, 2026Now RecruitingNow Active, not recruiting+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 89 studies in Breast Neoplasms by City of Hope Medical Center — 17 open to participants now, 39 under way, 1 of them phase 3. Breast Neoplasms · City of Hope Medical Center.

Planned enrollment
47th of 76
24 · median 36
Started
2025
with 5 others
Phase 1
14 of 89
2 open now
Primary completion
2029-03
later than 35 of 38 live
Registered
77th of 89
by date

Among the 89 studies in Breast Neoplasms by City of Hope Medical Center, this one is the 47th largest by planned enrollment of the 76 interventional ones that give a count, is one of 6 that started in 2025, is one of 14 in phase 1, reaches primary completion later than 35 of the 38 other live ones, and was the 77th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

17 of the 89 studies in Breast Neoplasms by City of Hope Medical Center are open now, in 1 country. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Breast Neoplasms by City of Hope Medical Center, or all of them as a file.
02

Study summary

This phase I trial studies the side effects and best dose of M5A-IL2 immunocytokine (M5A-ICK) combined with stereotactic body radiation therapy (SBRT) and to see how well they work in treating patients with colorectal cancer or xarcinoembryonic antigen (CEA) positive breast cancer that cannot be removed by surgery (unresectable) or has spread from where it first started (primary site) to other places in the body (metastatic). Carcinoembryonic Antigen (CEA) is a protein that is present in most colorectal cancers and in many other cancers, such as breast cancer, as well. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Cytokines are signaling proteins that help control inflammation in the body. They allow the immune system to mount a defense if germs or cancer or other substances that can make people sick enter the body. Interleukin-2 (IL-2) is a powerful cytokine able to regulate the immune responses that are important for anticancer immunity. Immunocytokines (also called antibody-cytokine fusion proteins) are small proteins that regulate the activity of immune cells. The M5A-IL2 immunocytokine (M5A-ICK) combines the cancer targeting features of the M5A antibody with the immune system regulation properties of the cytokine IL-2. Giving M5A-ICK in combination with standard of care (SOC) SBRT may work better in treating patients with unresectable metastatic colorectal cancer or CEA positive metastatic breast cancer.

Read the detailed description

PRIMARY OBJECTIVE:

I. Identify the maximum tolerated dose (MTD) and recommend phase 2 dose (RP2D) and characterize toxicities associated with administration of the M5A-IL2 after fractionated SBRT.

SECONDARY OBJECTIVES:

I. Describe the therapeutic response to treatment of irradiated and unirradiated tumors per Criteria in Solid Tumors version 1.1 (RECIST v 1.1) guidelines.

II. Describe AEs by M5A-IL2 dose level, per Common Terminology Criteria for Adverse Events [CTCAE] version 5.0.

III. Describe the pharmacokinetics of M5A-IL2. IV. Describe the frequency of auto-antibody formation, overall and by dose of M5A-IL2.

EXPLORATORY OBJECTIVE:

I. If medically feasible, tumors targeted for SBRT will be biopsied pre-SBRT and 1-2 weeks post 3rd dose of M5A-IL2.

OUTLINE: This is a dose-escalation study of M5A-ICK.

Patients undergo SOC SBRT over 3 fractions on days 1, 3, and 5, followed by M5A-ICK subcutaneously (SC) on days 8, 9, and 10 once daily for a single cycle on study. Patients undergo computed tomography (CT) or positron emission tomography (PET)/CT as well as blood sample collection throughout the trial. Patients may undergo magnetic resonance imaging or bone scan as clinically indicated on the trial. Additionally, patients may optionally undergo tissue biopsy during screening and on study.

After completion of study treatment, patients are followed-up at 3 months.

03

Conditions studied

  • Breast Carcinoma
  • Colorectal Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients should have a diagnosis of colon or rectal or breast cancer that is pathology proven
  • Patients should have a CEA producing colorectal cancer or breast cancer defined as a baseline CEA or prior documented CEA level exceeding 5 ng/ml or evidence of CEA staining by Immunohistochemistry (IHC)
  • Patients should 18 years of age or older
  • Patients are willing and capable to consent to study and to adhere with all elements of the study
  • Patients who have failed to respond to standard systemic therapy, or for whom standard or curative systemic therapy does not exist, is not tolerable or was refused
  • Patients should be at least 4 weeks from last receipt of a cytotoxic or biological agent prior to start of SBRT, with the exception of mitomycin C which requires a 6-week washout
  • Patients should have unresectable disease or not be a candidate for surgical resection
  • Patients must have a minimum of 1 and a maximum of 5 separate metastatic lesions planned for SBRT. (Patients may have > 5 metastatic lesions overall, however only up to 5 lesions will be treated with SBRT.) SBRT sites must be equal to or less than 5 cm in greatest dimension. SBRT treated sites must be measurable per 1.1 and can include metastatic sites in the lung, liver, or soft tissue. Sites that are intracranial or in the bone are excluded. Sites deemed not appropriate for SBRT by the treating radiation oncologist are also excluded
  • Patients should be at least 4 weeks from last radiation therapy prior to starting SBRT
  • Patients should be at least 4 weeks from any therapy prior to starting SBRT, with the exception of prior immunotherapy which would require a 3 month washout
  • Patients should have an (ECOG) performance status of 0-1
  • Patients should be considered clinically stable with an estimated overall survival of at least 3 months
  • > 1500/mm\^3
  • Lymphocyte count > 500/mm\^3
  • > 9 gm/dl
  • count > 100,000/mm\^3
  • (AST)/alanine transaminase (ALT) \< 2.5 x (ULN)
  • ≤ ULN
  • Patients should have adequate kidney function defined as a serum creatinine \< ULN or calculated of > 60ml/min (Cockroft-Gault formula)
  • Patients should have adequate cardiac function defined as:

    • No history of acute coronary syndromes (including myocardial infarction, unstable angina, Coronary artery bypass grafting (CABG), coronary angioplasty, or stenting) \< 12 months prior to screening
    • No impaired cardiovascular function or cardiovascular diseases, including any of the following:

      • Symptomatic chronic heart failure;
      • Evidence of clinically significant cardiac arrhythmias and/or conduction abnormalities
    • No uncontrolled arterial hypertension despite appropriate medical therapy (defined as systolic blood pressure > 160 or diastolic blood pressure >100)
    • (EKG) showing normal sinus rhythm and a (QTc) ≤ 450 ms for male and ≤ 470 ms for female patients
  • Patients should have adequate pulmonary function defined as:

    • Lack of uncontrolled pleural effusion requiring recurrent draining procedures (more than once per month)
    • Lack of oxygen supplementation dependence
  • All subjects must have the ability to understand and the willingness to sign a written
  • Screening 2-dimensional (2-D) echocardiogram (echo) shows a (LVEF) > 40%
  • Urinalysis shows lack of proteinuria or a maximum of 1+ proteinuria
  • Women of should use highly effective while receiving the trial regimen and for at least 5 half-lives of M5A-IL2 from the last dose of M5A-IL2

Exclusion criteria

Exclusion Criteria:

  • Patients on treatments including supra-physiological doses of
  • Patients with history of auto-immune disease including history of inflammatory bowel disease
  • Patients with active
  • Patients in the child-bearing ages who refuse to use adequate measures (example: contraceptives, barrier method, or abstinence)
  • Lactating females who do not agree to stop breastfeeding
  • Known active or C
  • Major surgical procedure within 4 weeks prior to SBRT
  • Non-healed wound or surgical incisions
  • Radiographic evidence of bowel obstruction
  • Electrolyte disturbances (sodium, potassium, magnesium, calcium, and phosphorous) that are not correctable to at least grade 1 with replacement therapy
  • Known of any of the study drug agents or components
  • Patients should not have any uncontrolled illness including ongoing or active infection
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study agents
  • Pregnant women are excluded from this study because the agents on this study are highly likely to exert teratogenic or abortifacient effects
  • Patients with other active are ineligible for this study
  • Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Treatment (SBRT, M5A-IL2 ICK)

    Patients undergo SOC SBRT over 3 fractions on days 1, 3, and 5, followed by M5A-ICK SC on days 8, 9, and 10 once daily for a single cycle on study. Patients undergo CT or PET/CT as well as blood sample collection throughout the trial. Patients may undergo magnetic resonance imaging or bone scan as clinically indicated on the trial. Additionally, patients may optionally undergo tissue biopsy during screening and on study.

    Procedure: Biopsy · Procedure: Biospecimen Collection · Procedure: Bone Scan · Procedure: Computed Tomography · Drug: Immunotherapy · Procedure: Magnetic Resonance Imaging · Procedure: Positron Emission Tomography · Radiation: Stereotactic Body Radiation Therapy

Interventions

  • ProcedureBiopsy

    Undergo tissue biopsy

    Also known as: BIOPSY_TYPE, Bx

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • ProcedureBone Scan

    Undergo bone scan

    Also known as: Bone Scintigraphy

  • ProcedureComputed Tomography

    Undergo CT or PET/CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography

  • DrugImmunotherapy

    Receive M5A-IL2 ICK SC

    Also known as: Immunological, Immunological Therapy, Immunologically Directed Therapy

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging

  • ProcedurePositron Emission Tomography

    Undergo PET/CT

    Also known as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT

  • RadiationStereotactic Body Radiation Therapy

    Undergo SBRT

    Also known as: SABR, SBRT, Stereotactic Ablative Body Radiation Therapy

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD) of the M5A-IL2 immunocytokine (M5A-ICK)

    Will be assessed following accelerated titration design 3, single patient cohorts will be used with dose doubling between cohorts until either a dose limiting toxicity (DLT) is observed, or 2 patients experience a moderate (grade 2) M5A-ICK related adverse event. At dose level 5, the design reverts to 3 patient cohorts (following the traditional 3+3 design) with 40% increments between dose levels. In the traditional 3+3 design, once 3 patients at a dose level are evaluable, if none has experienced a DLT, the dose can be escalated.

    Time frame: At the end of cycle 1 (each cycle is 28 days)

  2. Recommended phase 2 dose

    Will either be the MTD, or below, based on the full consideration of late adverse events, sub-DLT toxicities, clinical activity, and biological correlatives.

    Time frame: At the end of cycle 1 (each cycle is 28 days)

Secondary outcomes

  1. Therapeutic response to treatment

    Will be reported according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

    Time frame: Up to 2 years

  2. Incidence of adverse events

    All adverse events, including allergic reactions, hypertension, hypotension, and infusion reactions will be summarized in terms of dose level, type and frequency, data of onset and duration (where relevant) using Common Terminology Criteria for Adverse Events \[CTCAE\] version 5.0.

    Time frame: Up to 3 months after last M5A-ICK injection

  3. Number of participants with treatment-related auto-antibody formation

    Frequency of participants with auto-antibody formation, overall and by dose of M5A-IL2.

    Time frame: Screening, days 8 and 36, and 3 months

  4. Pharmacokinetics of M5A-IL2 (M5A-ICK blood clearance )

    Blood samples up to 4 days (based on the predicted ICK half life of 10 hours) will be used to determine M5A-ICK blood clearance by ELISA analysis using human CEA for capture and reporting with anti-IL2-HRP.

    Time frame: Pre-injection, approximately 1, 4 and 6 hours post injection on each day, and one sample done 1 and 2 days following the 3rd subcutaneous dose of M5A-IL2

07

Study locations

1 of 1 sites recruiting
08

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Mar 2029, 45 months after the start.

Of 373 non-industry phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 77. This study's planned 45 months is close to that.

Counting every sponsor, half of 763 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

Primary completion moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Mar 2029, last on Nov 3, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Mar 2029, last on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2023
First posted
Nov 14, 2023
StartActual
May 27, 2025
Primary completionEst.
Mar 5, 2029was Sep 2026
CompletionEst.
Mar 5, 2029was Sep 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting→Recruiting
changed Oct 5, 2026 · changed Oct 28, 2026
Sites
City of Hope Medical Center is now Recruiting
Oct 28, 2026
Primary completion
Sep 5, 2026→Mar 5, 2029
moved 2 times, Oct 5, 2026 – Nov 3, 2026
Study completion
Sep 5, 2026→Mar 5, 2029
moved 2 times, Oct 5, 2026 – Nov 3, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • City of Hope Medical Center · Duarte, United StatesContact added j•••@coh.org · •••4673Contact added (no phone or email listed)
Oct 28, 2026
Show all 3 updates
  1. Nov 3, 2026
    Primary completion Sep 5, 2028→Mar 5, 2029
    Study completion Sep 5, 2028→Mar 5, 2029
    + 1 other change: verification date
  2. Oct 28, 2026
    Active, not recruiting→Recruiting
    City of Hope Medical Center is now Recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • City of Hope Medical Center · Duarte, United StatesContact added j•••@coh.org · •••4673Contact added (no phone or email listed)
    + 1 other change: verification date
  3. Oct 5, 2026
    Recruiting→Active, not recruiting
    Primary completion Sep 5, 2026→Sep 5, 2028
    Study completion Sep 5, 2026→Sep 5, 2028
    + 3 other changes: verification date, site details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06130826
Responsible party
Sponsor
First posted
Nov 14, 2023
Start date
May 27, 2025
Primary completion
Mar 5, 2029 (estimated)
Completion
Mar 5, 2029 (estimated)
Last update
Nov 3, 2026

Study contacts

Jeffrey Y Wong
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion